Mithra Pharmaceuticals Sa

Hello and welcome to the METRA Half Year Results 2023. My name is Jess and I'll be your coordinator for today's event. Please note this call is being recorded and for the duration of the call, your lines will be on listen only. However, there will be the opportunity to ask questions. This can be done by pressing star one on your telephone keypad to register your question at any time. If at any point you require assistance, please press star zero and you'll be connected to an operator. I will now hand over to your host, Alex Sokolovsky, Head of Investor Relations, to begin today's call. Thank you.

Thank you, operator. And welcome, ladies and gentlemen, to the conference call on Mithra Pharmaceuticals financial results for the first six months of 2023. I'm Alex Sokolovsky, Head of Investor Relations for Mithra. Today's call is being recorded and a replay of this webcast and today's presentation slides will be made available later today on METRA's website. I'd like to call your attention to the forward-looking statements before I provide an overview of our agenda. Today's call contains forward-looking statements which are made based on information currently available to METRA and certain assumptions considered reasonable as of the date of this material. These forward-looking statements are not guarantees of future performance and actual operating results may differ substantially due to a number of factors. Today, our CEO, David Horn-Solomon, will make some introductory remarks before our CFO, Christophe Marchal, will guide us through the financial results highlights. Then David will cover the select operational highlights year to date. We will then hold the Q&A session before closing the call. David, the floor is yours.

Thank you very much, Alex, and welcome to everyone. I'm David Solomon. I'm the CEO of Mithra Pharmaceuticals, and I'm really glad you could all take the time today to join us for our 2023 half-year financial results. We've accomplished a lot already in this period. Some of the events we're going to report happened before I joined as CEO, but really under my leadership and with our management team, we're working hard to create what we now call Mithra 2.0, which is a company that will have strong results based on our assets, and we hope a new and valuable set of pipeline items that will be important for us as a biotech company and for all of you who are shareholders for creating value. Can we turn to the next slide, Alex? I want to tell you first about our fundamental strengths for success. At Mithra, we really work hard towards and using our innovative estetrol-based products to improve women's independence and improve women's health. Our lead products, as you know, based on estetrol, a novel fetal-based estrogen that has a differentiation from commonly used estrogens like estradiol or E2. Estetrol, often called E4, is the main product in our oral contraceptive called Estelle. We can announce now that in the U.S., we've launched sales and are ramping up, and we'll talk more about that. Estetrol or E4 is the singular product in Donesta where this medicine will be used to treat the symptoms of menopause, and we are now preparing for our U.S. NDA filing, and I'll tell you more about that. All of the work that we do is based on a very strong and experienced management team, and as I'll tell you, we've added some new members to the team who I believe will have a great impact on our future. We will talk also about our revenue growth and our strategic opportunities, specifically about the Novalon family of products. Novalon is a company wholly owned by Mitra, the Mitra Group, and it includes the product Myring, which is an implant that is a contraceptive, Tibalon for the treatment of the symptoms of menopause, and Zorilene that includes a feature for the treatment of prostate cancer. I'll also tell you a little bit later about the CDMO and how we hope to bring significant value to Mitra from our strategic options with the CDMO. But importantly, in Mitra 2.0, what we really hope to achieve is a new pipeline, a next generation of medicines for women's health that are innovative and important and valuable. And then together with Estelle and Genesta, we believe that this will bring significant value to the company especially as we also clean up our balance sheet. Next slide, please, Alex. Notable to run the company according to this vision is the need for a strong and experienced management team. I've met many of you already as chief executive officer, and I look forward to more engagement. Joining me as part of the management team are Graham Dixon, a very experienced scientist that has had significant experience at AstraZeneca and Galapagos. New to the company and joining us recently is Xavier Paoli in the role of Chief Operating Officer. Xavier brings a lot of experience from not only UCB GSK, but also Alexion that also was launching early products in Europe and in the United States. Joining us and continuing is our Chief Commercial Officer, Jean-Manuel Fontaine, who comes from Pfizer and Lundbeck experience and is a valued member of the team. And joining us on the call today is Christophe Maréchal, our Chief Financial Officer with deep experience in treasury controls and corporate financial strategy. Next slide. We've also added some key new members to the team to add to not only our integrity, but also our operations. Joining me in the office of the CEO is David Trude, who's the new Chief of Staff, or , or Chef du Cabinet, has deep experience from Pfizer, You've already met briefly now Alex Sokolovsky, who's now our head of investor relations that has a vast experience at BASF. And also new to the company and important in our role of communicating to all of you is our communications director, Frederic de Pretere, who comes with a significant experience also from here in Belgium. Now I'm going to pass the words to our chief financial officer, Christophe Marchal, who will give us our financial update. Christophe.